Arcus Biosciences (RCUS) Misses Q3 EPS by 5c

Arcus Biosciences (NYSE: RCUS) reported Q3 EPS of ($1.11), $0.05 worse than the analyst estimate of ($1.06). Revenue for the quarter came in at $9.46 million versus the consensus estimate of $9.47 million.

For earnings history and earnings-related data on Arcus Biosciences (RCUS) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• UBS Reiterates Neutral Rating on Lennar (LEN) Following Q2 Results
• Independent Bank receives regulatory approval for HCB Financial acquisition